Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3)

Verve Therapeutics Balance Sheet

Financials in millions BRL. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	246.57	229.55	193.74	183.26	188.52	371.79
Cash & Short-Term Investments	246.57	229.55	193.74	183.26	188.52	371.79
Cash Growth	58.99%	18.48%	5.72%	-2.79%	-49.30%	64.64%
Accounts Receivable	1,299	1,394	1,187	1,044	831.43	761.96
Other Receivables	526.38	535.83	600.78	498.23	448.16	403.15
Receivables	1,826	1,930	1,788	1,542	1,280	1,165
Inventory	1,622	1,820	1,528	1,236	1,085	903.84
Prepaid Expenses	11.51	12.26	10.43	6.61	8.72	9.32
Other Current Assets	33.24	28.25	19.66	13.16	20.55	34.08
Total Current Assets	3,739	4,020	3,539	2,980	2,582	2,484
Property, Plant & Equipment	733.43	674.18	535.59	507	519.02	392.62
Long-Term Investments	1.95	2.04	2.01	1.99	-	36.46
Goodwill	482.66	486.28	483.16	488.01	495.02	500.58
Other Intangible Assets	145.66	143.04	134.74	131.47	129.31	123.89
Long-Term Deferred Tax Assets	215.67	234.13	184.1	177.08	163.7	121.86
Other Long-Term Assets	52.6	56.48	58.96	78.96	143.84	101.51
Total Assets	5,371	5,616	4,938	4,365	4,033	3,761
Accounts Payable	1,716	2,195	1,820	1,486	1,286	1,146
Accrued Expenses	99.94	91.68	69.29	147.6	119.73	130.38
Current Portion of Long-Term Debt	719.78	248.54	206.28	131.02	117.65	167.47
Current Portion of Leases	112.92	110.67	92.51	90.91	89.18	66.75
Current Income Taxes Payable	120.79	130.24	106.65	0.18	0.15	0.08
Current Unearned Revenue	11.21	109.51	49.37	21.51	46.54	-
Other Current Liabilities	97.62	103.14	102.07	79.48	57.22	33.51
Total Current Liabilities	2,878	2,989	2,447	1,956	1,717	1,544
Long-Term Debt	371.06	551.18	573.63	532.65	440.8	433.64
Long-Term Leases	378.1	336.32	271.28	269.62	299.25	232.86
Long-Term Deferred Tax Liabilities	54.48	82.12	40.22	41.42	38.06	27.38
Other Long-Term Liabilities	67.79	71.66	67.13	54.33	62.02	88.11
Total Liabilities	3,750	4,030	3,399	2,854	2,557	2,326
Common Stock	918.66	918.66	1,044	1,044	1,044	1,044
Retained Earnings	257.59	224.15	180.07	156.97	97.35	52.33
Treasury Stock	-16.37	-16.37	-16.37	-16.37	-16.37	-16.37
Comprehensive Income & Other	176.5	176.66	40.98	6.74	-38.58	-33.31
Total Common Equity	1,336	1,303	1,248	1,191	1,086	1,046
Minority Interest	284.48	282.72	290.68	319.58	389.82	388.9
Shareholders' Equity	1,621	1,586	1,539	1,511	1,476	1,435
Total Liabilities & Equity	5,371	5,616	4,938	4,365	4,033	3,761
Total Debt	1,582	1,247	1,144	1,024	946.88	900.72
Net Cash (Debt)	-1,335	-1,017	-949.96	-840.94	-758.37	-528.93
Net Cash Per Share	-10.89	-8.30	-7.75	-6.86	-6.19	-4.31
Filing Date Shares Outstanding	122.61	122.61	122.61	122.61	122.61	122.61
Total Common Shares Outstanding	122.61	122.61	122.61	122.61	122.61	122.61
Working Capital	860.32	1,031	1,093	1,024	865.12	940.29
Book Value Per Share	10.90	10.63	10.18	9.71	8.86	8.53
Tangible Book Value	708.06	673.79	630.44	571.54	461.74	421.85
Tangible Book Value Per Share	5.77	5.50	5.14	4.66	3.77	3.44
Machinery	306.18	280.59	236.64	215.69	194.07	173.49
Construction In Progress	6.67	6.81	14.23	6.22	9.33	7.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.